TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21443993

Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA) for self-monitoring
Number of subjects: 192

Group type: COMPARATOR
Intervention: Paper record for self-monitoring
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups (PDA and Paper record)
Number of subjects: 192
Study: 19801029

Group type: COMPARATOR
Intervention: Intravenous heparin (50 U/kg, max 5,000 U)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intra-arterial heparin (50 U/kg, max 5,000 U)
Number of subjects: 500
Study: 16891758

Group type: EXPERIMENTAL
Intervention: Daily walking for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15577595

Group type: EXPERIMENTAL
Intervention: Solid gastric emptying parameters (T1/2, TRE)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Solid gastric emptying parameter (Tlag)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Liquid gastric emptying parameters
Number of subjects: 476

Group type: COMPARATOR
Intervention: Gastric emptying (GE) classification
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Correlation between solid T1/2 and TRE
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: GE parameters in patients with normal results
Number of subjects: 476
Study: 11740297

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate and glucose (CR-CHO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Protein and glucose (PRO-CHO)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both CR-CHO and PRO-CHO
Number of subjects: 19
Study: 9005908

Group type: EXPERIMENTAL
Intervention: Advanced cementing technique (canal irrigation, brushing and drying with gauze, canal plugging, low viscosity cement pressurization with a delivery system)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional cementing technique (doughy cement manually inserted and packed)
Number of subjects: 16
Study: 7901979

Group type: EXPERIMENTAL
Intervention: Electromyostimulation during follow-up treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open knee joint operations and arthroscopically controlled reconstruction operations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injury alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follow-up treatment
Number of subjects: 0
Study: 3425350

Group type: EXPERIMENTAL
Intervention: Enprofylline (mean plasma concentration 3 mg l‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Theophylline (mean plasma concentration 9 mg l‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31112053

Group type: EXPERIMENTAL
Intervention: Baby-Friendly Hospital Initiative compliance assessment
Number of subjects: 180
Study: 30219823

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX) 5-15 mg/week
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (plus folic acid)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LDMTX)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 27630212

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671

Group type: EXPERIMENTAL
Intervention: DPP-4i therapy (including sitagliptin)
Number of subjects: 14671
Study: 25371077

Group type: EXPERIMENTAL
Intervention: Pemetrexed + Carboplatin (Pem+Cb)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin + Bevacizumab (Pac+Cb+Bev)
Number of subjects: 361
Study: 23061387

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg intravenous every 12 hours)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg intravenous every 6 hours)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Omeprazole (high-dose: 80 mg bolus plus 8 mg/hr infusion for 3 days, then 40 mg intravenous every 12 hours for 7 days)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 165
Study: 21216122

Group type: EXPERIMENTAL
Intervention: Ten-cha (Rubus suavissimus) 400mg (3 capsules/day) for 4 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (3 capsules/day) for 4 weeks
Number of subjects: 89
Study: 19893562

Group type: EXPERIMENTAL
Intervention: Local anaesthetic and analgesics
Number of subjects: 198

Group type: COMPARATOR
Intervention: Post-operative ECG monitoring
Number of subjects: 198
Study: 16843192

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination therapy (Simvastatin 20 mg + Fenofibrate 160 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 300
Study: 12576122

Group type: EXPERIMENTAL
Intervention: High-fat milkshake
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low-fat milkshake
Number of subjects: 192
Study: 11164436

Group type: EXPERIMENTAL
Intervention: epsilon44 genotype in hypercholesterolemic patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: epsilon32 genotype in hypercholesterolemic patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: epsilon22 genotype in hypertriglyceridemic patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: epsilon42 genotype in hypertriglyceridemic patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: epsilon43 genotype in hypertriglyceridemic patients
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: epsilon44 genotype in hypertriglyceridemic patients
Number of subjects: 239
Study: 9359441

Group type: EXPERIMENTAL
Intervention: Serial monitoring by cardiotocography and measurement of amniotic fluid index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate induction
Number of subjects: 0
Study: 8267390

Group type: EXPERIMENTAL
Intervention: Adjuvant perioperative portal infusion with Fluorouracil and Mitomycin
Number of subjects: 533

Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 533
Study: 3512326

Group type: EXPERIMENTAL
Intervention: Acyclovir cream applied 4 times per day for 16 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo cream applied 4 times per day for 16 weeks
Number of subjects: 23
Study: 30888235

Group type: EXPERIMENTAL
Intervention: Partial canal wall preserved tympanomastoidectomy (PCM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Canal wall down tympanomastoidectomy (CWD)
Number of subjects: 39
Study: 28815419

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily for the first week, then 100 mg for the following seven weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 25154706

Group type: EXPERIMENTAL
Intervention: Intramuscular typhoid vaccination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (intramuscular saline)
Number of subjects: 16
Study: 23758145

Group type: EXPERIMENTAL
Intervention: Routine care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensive case management and/or in-depth interviews
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 20
Study: 21252013

Group type: EXPERIMENTAL
Intervention: Autologous skeletal myoblast therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 40
Study: 19368899

Group type: EXPERIMENTAL
Intervention: Computerized auditory training (50 hours over 10 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Computer game control condition
Number of subjects: 56
Study: 17357282

Group type: EXPERIMENTAL
Intervention: Extracorporeal ultraviolet light-exposure (UVLE)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Biospecific hemosorption (BSS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: BSS plus UVLE
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard treatment with antibiotics
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All EED methods (UVLE and BSS)
Number of subjects: 103
Study: 14731308

Group type: EXPERIMENTAL
Intervention: Combined monoamine depletion (CMD; via tryptophan, tyrosine and phenylalanine depletion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balanced control condition (B)
Number of subjects: 20
Study: 11480646

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations (4-META-based resin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pin-retained amalgam restorations (self-threading pins)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (bonded and pin-retained)
Number of subjects: 60
Study: 10194995

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 8064049

Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy
Number of subjects: 11
Study: 2691069

Group type: EXPERIMENTAL
Intervention: Madopar CR (controlled‐release levodopa plus benserazide)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard Madopar
Number of subjects: 103
Study: 4557029

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study: 28730741

Group type: EXPERIMENTAL
Intervention: Motivational feedback from coach
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Motivational feedback from athlete leader
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Motivational feedback from both coach and athlete leader
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no motivational feedback)
Number of subjects: 120
Study: 26814715

Group type: EXPERIMENTAL
Intervention: SeCTG + TT
Number of subjects: 50

Group type: COMPARATOR
Intervention: SeCTG + CAF
Number of subjects: 50
Study: 24729145

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 23578860

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 120
Study: 20179125

Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 314

Group type: COMPARATOR
Intervention: Repeat smear test at six months
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Informed choice of either test supported by a decision aid
Number of subjects: 314
Study: 18450843

Group type: EXPERIMENTAL
Intervention: Specialist nurse‐led disease management programme
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Control group (standard general practice care)
Number of subjects: 1163
Study: 16600924

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 50 mug/d plus 500 mg Ca/d
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo plus 500 mg Ca/d
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study: 14750575

Group type: EXPERIMENTAL
Intervention: Prednisolone treatment starting at 40 mg per day, tapering over 4 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 11203411

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (250 pg/12 hours) for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 94
Study: 8725679

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 430

Group type: COMPARATOR
Intervention: Missed dialysis treatments
Number of subjects: 430
Study: 1564415

Group type: EXPERIMENTAL
Intervention: Lower cervical adjustments (C6‐C7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper cervical adjustments (C2‐C3)
Number of subjects: 0
Study: 3909958

Group type: EXPERIMENTAL
Intervention: ACV-recombinant human alpha 2 IFN (eyedrops and eyerods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACV-IFN combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACV-Placebo combination
Number of subjects: 0
Study: 30702372

Group type: EXPERIMENTAL
Intervention: 6 mg·kg‐1 of caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg·kg‐1 of caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 mg·kg‐1 of caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28797202

Group type: EXPERIMENTAL
Intervention: Responses to smiles of joy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responses to tears of joy
Number of subjects: 0
Study: 26653674

Group type: EXPERIMENTAL
Intervention: TM-training (12-cm slip)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TM-training (18-cm slip)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no perturbation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: OG-training (overground perturbation training)
Number of subjects: 36
Study: 24661791

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (HFS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-frequency stimulation (LFS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: DBS-OFF
Number of subjects: 17
Study: 24330763

Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (six automated voice messages for family planning support)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention
Number of subjects: 500
Study: 20535950

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study: 17690882

Group type: EXPERIMENTAL
Intervention: RBC transfusion to maintain Hb levels >or=10 g/dl (arm 1)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: RBC transfusion to maintain Hb levels >or=12 g/dl (arm 2)
Number of subjects: 87
Study: 15725943

Group type: EXPERIMENTAL
Intervention: NaCl (saline load)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 18
Study: 12667975

Group type: EXPERIMENTAL
Intervention: Herbal practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10686454

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 2.0-3.0)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole (400 mg daily) plus aspirin (30-325 mg daily)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 4500
Study: 8672381

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.5 mg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 1387073

Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin and sulfonylurea
Number of subjects: 17

Group type: COMPARATOR
Intervention: Insulin therapy alone (control group)
Number of subjects: 17
Study: 2433310

Group type: EXPERIMENTAL
Intervention: Home intervention focusing on the development of the infant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home intervention focusing on the parent-infant interaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 31909423

Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied once
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied three times
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brood interruption
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied once + brood interruption
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied three times + brood interruption
Number of subjects: 60

Group type: COMPARATOR
Intervention: No OA or brood interruption
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitraz (Apivar - positive control)
Number of subjects: 60
Study: 29990690

Group type: EXPERIMENTAL
Intervention: ReciGen®
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Rebif®
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ReciGen® or Rebif® for >24 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: ReciGen® and Rebif®
Number of subjects: 71
Study: 27604335

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL-148)
Number of subjects: 70
Study: 25439449

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 16304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16304
Study: 23110676

Group type: EXPERIMENTAL
Intervention: Three-factor model (pain intensity, activity interference, affective interference)
Number of subjects: 184
Study: 19804593

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (5-ALA) patch-PDT
Number of subjects: 316

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 316
Study: 22944145

Group type: EXPERIMENTAL
Intervention: CYFRA 21‐1
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: NMP22
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: UBC
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: FDP
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combination of markers
Number of subjects: 250
Study: 16424843

Group type: EXPERIMENTAL
Intervention: L-glutamate (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (n = 10)
Number of subjects: 20
Study: 12856386

Group type: EXPERIMENTAL
Intervention: Tinzaparin (mean MW = 6500 Da; 3.5% of fractions < 2000 Da)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tinzaparin-like LMWH (mean MW = 5650 Da; 18.3% of fractions < 2000 Da)
Number of subjects: 30
Study: 10212170

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% solution, 5 ml/kg for 30 minutes)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8588166

Group type: EXPERIMENTAL
Intervention: Low back pain group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline disc degeneration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial disc protrusion
Number of subjects: 0
Study: 2575521

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (P40)
Number of subjects: 5
Study: 30321084

Group type: EXPERIMENTAL
Intervention: NMES + EX
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 51
Study: 31124147

Group type: EXPERIMENTAL
Intervention: 6 mm implants alone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 8 mm implants + OSFE
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 10 mm implants + OSFE
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 225
Study: 28701288

Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (33 μg kg−1 loading dose, 0.2 μg kg−1 minute−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High dose fentanyl (102 μg kg−1 loading dose, 0.8 μg kg−1 minute−1)
Number of subjects: 8
Study: 26664151

Group type: EXPERIMENTAL
Intervention: L-carnitine 600 mg oral daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 23814841

Group type: EXPERIMENTAL
Intervention: Passive prolonged drainage of a perineal wound
Number of subjects: 0
Study: 21668522

Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg day(-1) for adults; 2 mg kg(-1) day(-1) for children)
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Micafungin (100 or 150 mg day(-1))
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1))
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Caspofungin (50 mg day(-1); 70 mg loading dose)
Number of subjects: 1061

Group type: COMPARATOR
Intervention: All drugs (Micafungin, L-AmB, Caspofungin)
Number of subjects: 1061
Study: 18295615

Group type: EXPERIMENTAL
Intervention: Twelve‐week adherence intervention (weekly phone calls and home visit) including counseling on establishing, monitoring, and problem‐solving in maintaining a home exercise program
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study: 16932345

Group type: EXPERIMENTAL
Intervention: Non-infusional consolidation chemotherapy (mini-ICE regimen)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Intravenous consolidation chemotherapy (mini-ICE regimen)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Both non-infusional and intravenous consolidation chemotherapy
Number of subjects: 346
Study: 12932938

Group type: EXPERIMENTAL
Intervention: Cavernous arterial insufficiency in men aged 50 to 59 years
Number of subjects: 158

Group type: COMPARATOR
Intervention: No cavernous arterial insufficiency in men aged 50 to 59 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cavernous arterial insufficiency in men aged 40 to 49 years and 60 to 69 years
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Overall population of men with ED
Number of subjects: 158
Study: 10883562

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study: 9334893

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily for 20 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (after withdrawal from fluoxetine)
Number of subjects: 14
Study: 1492275

Group type: EXPERIMENTAL
Intervention: cinoxacin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: pefloxacin
Number of subjects: 150
Study: 2930987

Group type: EXPERIMENTAL
Intervention: 100 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol) for 9 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 25 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High dose CA
Number of subjects: 34